A partnership between the FDA and the American Society of Clinical Oncology's CancerLinQ provides regulators with timely, real-world data on newly approved cancer therapies. The alliance may help investigators gain insights and assess the impact of drugs in patient populations that are not well represented in traditional clinical trials.
http://ift.tt/2w28FHq
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου